Literature DB >> 9081676

A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants.

S H Wild1, S P Fortmann, S M Marcovina.   

Abstract

Lipoprotein(a) [Lp(a)] is formed by the assembly of LDL particles and a carbohydrate-rich protein, apolipoprotein(a) [apo(a)], which has a high degree of structural homology with plasminogen. While the majority of retrospective studies have found an association between Lp(a) level and cardiovascular disease (CVD), the few prospective studies to date have reported contradictory results. We conducted a nested case-control study using the participants in the Stanford Five-City Project, a long-term CVD prevention trial. Participants with an incident possible or definite myocardial infarction or coronary death were matched to a single control subject for age, sex, ethnicity, residence in a treatment or control city, and time of survey. This process yielded 134 case-control pairs, 90 male and 44 female, for whom plasma was available for analysis of Lp(a). Lp(a) values in nanomoles per liter were determined by an enzyme-linked immunoassay that measures Lp(a) independently of apo(a) size polymorphism. Apo(a) size isoforms were determined by SDS-agarose gel electrophoresis. Median Lp(a) level in male cases was almost double that in control subjects (41.8 versus 21.2 nmol/L; P < .01); in female cases, median Lp(a) was 34% higher than in control subjects (32.5 versus 21.2 nmol/L), but this difference was not statistically significant. Among the male cases, there was an increased frequency of small apo(a) isoforms, while no significant difference was found in apo(a) size between female cases and control subjects. The association between Lp(a) level and case-control status in men was independent of total, HDL, and non-HDL cholesterol levels, as well as apo(a) size isoform, cigarette smoking, blood pressure, and obesity. In men, the most efficient threshold value of Lp(a) concentration for separating cases and control subjects was 35 nmol/L; the odds ratio for being a case above this level compared with below was 2.84 (95% confidence interval: 1.53-5.27, P < .001). This study provides strong evidence that Lp(a) level is a prospective, independent risk factor for developing coronary artery disease in men and indicates that the size of apo(a) may also play a role. The lack of a significant association in women deserves further evaluation in larger studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9081676     DOI: 10.1161/01.atv.17.2.239

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  25 in total

Review 1.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

Review 2.  Novel markers of inflammation in atherosclerosis.

Authors:  Salim S Virani; Venkateshwar R Polsani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

Review 3.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 4.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

Review 5.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

6.  Analysis of cholesterol levels in lipoprotein(a) with anion-exchange chromatography.

Authors:  Yuji Hirowatari; Hiroshi Yoshida; Hideo Kurosawa; Yuko Shimura; Hidekatsu Yanai; Norio Tada
Journal:  J Lipid Res       Date:  2009-10-30       Impact factor: 5.922

Review 7.  Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications.

Authors:  Angelo M Scanu
Journal:  Curr Atheroscler Rep       Date:  2003-03       Impact factor: 5.113

Review 8.  Plasma lipoprotein concentrations in ethnic populations.

Authors:  Karol E Watson
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 9.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

Review 10.  Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.

Authors:  Eva Boes; Stefan Coassin; Barbara Kollerits; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-11-17       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.